Testing apalutamide in early prostate cancer active surveillance
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 trial tests whether apalutamide can help people with early prostate cancer who choose active surveillance. It uses MRI and biopsy results to confirm the cancer type and location, then checks if treatment is safe and potentially helpful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and willing to sign the study consent form
- Be able to be active in daily life (ECOG 0 to 2)
- Choose active surveillance for your prostate cancer as your plan for now
- Your prostate MRI must show a suspicious lesion (by PI-RADS or M score) that meets size criteria, and your biopsy results must match the MRI
- You should not need bladder outlet surgery during treatment or for the next 12 months
- Your recent blood tests and heart/kidney/liver measures must be within required safety ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether men with low-risk prostate cancer can safely avoid treatment by closely monitoring their cancer over many years. It tests a new approach to see if it is better than the current standard of care.
This trial studies a “watchful waiting” approach, where doctors closely monitor certain prostate cancers with regular checkups and repeat biopsies. It may help people avoid or delay treatment side effects while watching for signs the cancer needs treatment.
This Phase 2 study tests whether adding apalutamide to standard hormone therapy (ADT) after prostate surgery can lower the chance that prostate cancer comes back. It targets men at higher risk of recurrence based on PSA levels and a risk score from surgical findings.
This study follows men with low-risk prostate cancer who choose active surveillance (watching closely instead of immediate treatment). It aims to better track which monitoring results stay reassuring over time, and when treatment might be needed.
This study tests whether watching low-risk prostate cancer closely (instead of treating right away) is safe. It may help some people avoid early treatments and their side effects while still keeping a close eye on the cancer.
This trial follows men with prostate cancer who choose “active surveillance” instead of immediate treatment. It tests whether careful tracking (including patient reports) can help manage cancer over time and guide decision-making.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.